OCUL - Ocular Therapeutix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.62
+0.18 (+2.80%)
At close: 4:00PM EDT

6.62 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close6.44
Open6.46
Bid5.80 x 4000
Ask6.90 x 900
Day's Range6.46 - 6.70
52 Week Range3.30 - 8.28
Volume542,711
Avg. Volume387,814
Market Cap255.48M
Beta0.88
PE Ratio (TTM)N/A
EPS (TTM)-1.72
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.33
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents14 days ago

    Edited Transcript of OCUL earnings conference call or presentation 7-Aug-18 8:30pm GMT

    Q2 2018 Ocular Therapeutix Inc Earnings Call

  • Here's Why Ocular Therapeutix Jumped 21.6% in August
    Motley Fool15 days ago

    Here's Why Ocular Therapeutix Jumped 21.6% in August

    The company reported second-quarter 2018 financial results and an important business update.

  • Business Wire27 days ago

    Ocular Therapeutix™ to Present at the H.C. Wainwright 20th Annual Global Investment Conference

    Ocular Therapeutix, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will present at the H.C.

  • GlobeNewswire29 days ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Lindblad Expeditions, Milacron, Lantheus, RCI Hospitality, Ingles Markets, and Ocular Therapeutix — New Research Emphasizes Economic Growth

    NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Lindblad ...

  • GuruFocus.comlast month

    Ocular Therapeutix Inc (OCUL) President & CEO Antony C. Mattessich Bought $119,000 of Shares

    President & CEO of Ocular Therapeutix Inc (NASDAQ:OCUL) Antony C. Mattessich bought 20,000 shares of OCUL on 08/20/2018 at an average price of $5.95 a share.

  • JMP Highlights Two Biotech Stocks to Consider Ahead of Upcoming FDA Decisions: Trevena (TRVN), Ocular (OCUL)
    SmarterAnalystlast month

    JMP Highlights Two Biotech Stocks to Consider Ahead of Upcoming FDA Decisions: Trevena (TRVN), Ocular (OCUL)

    Both companies are due to have important FDA catalysts that could lead to a share price turnaround. Last year, Trevena (NASDAQ:TRVN) submitted a New Drug Application (NDA) for oliceridine, the first G protein biased ligand of the mu receptor designed to provide IV opioid pain relief with fewer side effects. The FDA will have an AdComm meeting before the PDUFA date on November 2, 2018. According to CEO Maxine Gowen, the company remains in active discussions for oliceridine licensing in the US as it gets closer to commercialization.

  • Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates

    Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 0.00% and 85.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Ocular Therapeutix: 2Q Earnings Snapshot

    The Bedford, Massachusetts-based company said it had a loss of 37 cents per share. The biotechnology company posted revenue of $648,000 in the period. Ocular Therapeutix shares have increased 24 percent ...

  • Business Wire2 months ago

    Ocular Therapeutix™ Reports Second Quarter 2018 Financial Results and Business Update

    DEXTENZA® NDA Resubmission Submitted and Accepted by the U.S. Food and Drug Administration

  • Business Wire2 months ago

    Ocular Therapeutix™ To Report Second Quarter 2018 Financial Results

    Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter ended June 30, 2018 financial results on Tuesday, August 7, 2018. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the Company’s financial results and provide a general business update. The live webcast can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com.

  • Business Wire2 months ago

    Ocular Therapeutix™ Announces FDA Acceptance of NDA Resubmission for DEXTENZA®

    Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has received acknowledgement from the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for DEXTENZA® has been received. DEXTENZA (dexamethasone insert) 0.4mg is Ocular Therapeutix’s lead product candidate for the treatment of ocular pain following ophthalmic surgery.

  • Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy?
    Zacks2 months ago

    Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy?

    Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy?

  • Ocular Therapeutix (OCUL) Enters Oversold Territory
    Zacks2 months ago

    Ocular Therapeutix (OCUL) Enters Oversold Territory

    Ocular Therapeutix, Inc. (OCUL) has been on a bit of a cold streak lately

  • Business Wire3 months ago

    Ocular Therapeutix™ Announces NDA Resubmission of DEXTENZA™

    Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company’s New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate DEXTENZA™ (dexamethasone insert) 0.4mg, for the treatment of ocular pain following ophthalmic surgery. The resubmission is intended to address manufacturing deficiencies cited by the FDA in the Agency’s July 2017 Complete Response Letter.

  • Business Wire3 months ago

    Ocular Therapeutix™ to Present at the 2018 JMP Securities Life Sciences Conference

    Ocular Therapeutix, Inc. a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will present at the 2018 JMP Securities Life Sciences Conference on Wednesday, June 20, 2018 at 3:30 PM ET at the St.

  • 5 Clinical-Stage Biotech Stocks to Buy Under $10
    InvestorPlace4 months ago

    5 Clinical-Stage Biotech Stocks to Buy Under $10

    After all, the thrill of getting a big-time approval or even making through to the next round of FDA trail phases can send a biotech stock’s price surging. The key is in finding those smaller drug firms that have the ability to actually get through clinical trials and start marketing drugs. Likewise, spreading your money around to a variety of clinical stage names is also paramount if you want to play in the space.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of OCUL earnings conference call or presentation 8-May-18 8:30pm GMT

    Q1 2018 Ocular Therapeutix Inc Earnings Call

  • Associated Press5 months ago

    Ocular Therapeutix: 1Q Earnings Snapshot

    On a per-share basis, the Bedford, Massachusetts-based company said it had a loss of 40 cents. The biotechnology company posted revenue of $340,000 in the period. Ocular Therapeutix shares have increased ...

  • Business Wire5 months ago

    Ocular Therapeutix™ Reports First Quarter 2018 Financial Results and Business Update

    Ocular Therapeutix™, Inc. , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the first quarter ended March 31, 2018 and provided a business update.

  • Business Wire5 months ago

    Ocular Therapeutix™ Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Glaucoma and Ocular Hypertension

    Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the treatment of the first patient in a Phase 1, open-label, proof-of-concept clinical trial being conducted in the United States for OTX-TIC, a bioresorbable travoprost implant delivered via an intracameral injection for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. “One of the biggest unmet needs in ophthalmology, and in glaucoma in particular, is solving the problem of non-compliance,” said Michael Goldstein, M.D., Chief Medical Officer of Ocular Therapeutix.

  • Business Wire5 months ago

    Ocular Therapeutix™ to Present Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

    Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that data from its preclinical research will be highlighted in presentations and posters at the Association for Research in Vision and Ophthalmology Annual Meeting, April 29 – May 3, in Honolulu, HI.

  • Business Wire5 months ago

    Ocular Therapeutix™ to Report First Quarter 2018 Financial Results

    Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter ended March 31, 2018 financial results on Tuesday, May 8, 2018. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the Company’s financial results and provide a general business update. The live webcast can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com.

  • Business Wire6 months ago

    Ocular Therapeutix™ to Present Data at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium

    Ocular Therapeutix, Inc.  , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced data from its clinical and preclinical research will be highlighted in presentations at the combined American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators ...